FLRY3
Fleury S.A.Report (Preview)
Detailed and complete analysis about this companyAccess full B3 reports
Full analysis — FLRY3 is available only for Premium subscribers.
With Premium you have access to detailed reports of all companies, with valuation and fair price.
Price Chart
Data provided by TradingView
Loading chart...
Analyst Recommendations
Valuation Multiples
Margins & Profitability
Growth
Dividends
Moving Averages
Average Volume
Dividend History (12m)
Price Evolution (12m)
Seasonality Study
Historical monthly performance of the asset over the last 11 years. Helps identify seasonal behavior patterns.
Avg Return (%)
High Frequency (%)
Best Month
2nd Best
High Frequency
High Frequency
Balance Sheet
| Period | Total Assets | Liabilities | Total Equity |
|---|---|---|---|
| 2025 | R$13.2B | R$8.12B | R$5B |
| 2024 | R$13.1B | R$7.69B | R$5.29B |
| 2023 | R$11.6B | R$6.47B | R$5.08B |
| 2022 | R$7.79B | R$5.09B | R$2.68B |
MyHub Discussion (0)
About the Company
Fleury S.A., together with its subsidiaries, engages in the provision of diagnostic imaging, clinical analysis, fertility, and infusions services in Brazil. It operates in two segments, Diagnostic Medicine and Integrated Medicine. The company also provides medical services in the areas of diagnostics, laboratory support, infusions, clinical analyses, health management, healthcare, assistance medicine, orthopedics, ophthalmology, toxicological tests, fertility, infusions, and others. In addition, it operates a health platform, immunobiological drug infusion center, and ophthalmology service centers. Fleury S.A. was founded in 1926 and is headquartered in São Paulo, Brazil.
Market Data
- Market CapR$10.91B
- Min 52sMax 52sR$13.90R$28.65
- Average Volume8.1M